This excerpt taken from the CRIS 8-K filed Dec 20, 2006.
Michael P. Gray, who most recently held the position of Senior Vice President of Finance and Chief Financial Officer, will assume the additional role of Chief Operating Officer, while retaining the responsibilities and title of Chief Financial Officer. Gray will continue to have primary responsibility over a majority of Curis administrative functions and will now have a greater role in aligning Curis promising drug development programs with the companys overall corporate objectives and operating budget.
Mike Gray has been an important part of the Curis team and has consistently demonstrated strong management and leadership skills during his tenure, said Dan Passeri, President and Chief Executive Officer of Curis. He has provided solid financial and administrative oversight throughout his three years as Curis Chief Financial Officer and was also instrumental in implementing various aspects of our recent entry into China. I will be looking to Mike to lead the coordination of the companys drug development and administrative efforts as we seek to move our drug programs into later stages of development in a highly effective and cost-efficient manner.
In addition, Curis recently promoted Dr. Changgeng Qian to the position of Vice President, Discovery and Preclinical Development. Dr. Qian joined Curis in 2001, bringing more than 25 years of academic and industrial experience in drug discovery, including
pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety assessment. He has played key roles in the discovery and development of several drug candidates, including cancer and central nervous system indications at CytoMed, Inc., LeukoSite, Inc., and Millennium Pharmaceuticals, Inc.
Noted Passeri, Dr. Qian brings tremendous experience and scientific leadership to his new role. He has been an invaluable asset to Curis, both in his guidance surrounding Curis programs under collaboration, and in his leadership in directing Curis wholly-owned and proprietary multi-targeted inhibitor (MTI) programs. We are extremely pleased to have someone of Dr. Qians caliber leading these scientific efforts.